Proof of Concept for a Platform for the Fast and General Elucidation of the Inte...
Proof of Concept for a Platform for the Fast and General Elucidation of the Interaction Between Proteins and RNA
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to establish proof-of-concept of the utility of a new platform for fast and general elucidation of the interaction betw...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
meltRBP
Tracking interactions between RNA and RNA binding proteins b...
171K€
Cerrado
RBP-ReguNet
Deconstructing and Rewiring RNA RBP regulatory networks
3M€
Cerrado
FORGENOM II
Fostering Excellence in Advanced Genomics and Proteomics Res...
1M€
Cerrado
PRIME-XS
Proteomics Research Infrastructure Maximising knowledge EXch...
10M€
Cerrado
SAF2017-90781-REDI
FOMENTO DEL USO DE LAS TECNOLOGIAS OMICAS EN MEDICINA PERSON...
79K€
Cerrado
RNA_REGULOMICS
The role of non coding RNA in human health and disease
155K€
Cerrado
Información proyecto ProteRNA
Duración del proyecto: 49 meses
Fecha Inicio: 2020-11-24
Fecha Fin: 2024-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The aim of this project is to bring together subject matter experts from the academic and non-academic sectors to establish proof-of-concept of the utility of a new platform for fast and general elucidation of the interaction between proteins and RNA. The development of analytical methods for identification of RNA-binding proteins (RPBs) and their corresponding RNA motifs, will permit and accelerate: i) a deeper understanding of the roles of gene regulation and protein expression; ii) development of personalised medicines via regulation of protein expression; and iii) rapid identification of proteomes involved in specific diseases. In doing so, this project will have outputs which have significant market opportunities and societal benefits, including, but not limited to, stimulating job creation in the pharmabiotech and diagnostics sectors and reducing costs for national and EU healthcare budgets.